Sex differences in methamphetamine-evoked striatal dopamine output are abolished following gonadectomy: Comparisons with potassium-evoked output and responses in prepubertal mice

Neuroendocrinology

Volumn 82, Issue 2, 2005, Pages 78-86

  Dluzen, Dean E ^a   Salvaterra, Ty J ^a  

^a Northeastern Ohio Medical University   (United States)

Author keywords

Catecholamines; Gonadal steroids; Metamphetamine; Neurotoxicity; Prepubertal mice; Sex dimorphism; Striatum

Indexed keywords

DOPAMINE; METHAMPHETAMINE; POTASSIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOPAMINE RELEASE; DOSE RESPONSE; EVOKED RESPONSE; FEMALE; GONADECTOMY; INFUSION; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PREPUBERTY; PRIORITY JOURNAL; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; STRIATE CORTEX;

ANIMALS; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; FEMALE; MALE; METHAMPHETAMINE; MICE; NEOSTRIATUM; ORCHIECTOMY; OVARIECTOMY; POTASSIUM; SEX CHARACTERISTICS; SEXUAL MATURATION;

EID: 33644541120     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000090983     Document Type: Article

References (50)

1. Crowley WR, O'Donohue TL, Jacobowitz DM: Sex differences in catecholamine content in discrete brain nuclei of the rat: effects of neonatal castration or testosterone treatment. Acta Endrinol 1978;89:20-28.
2. Becker J, Ramirez VD: Sex differences in the amphetamine stimulated release of catecholamines from rat striatal tissue in vitro. Brain Res 1981;204:361-372.
3. Fernandez-Ruiz J, de Miguel R, Hernandez HL, Cebeira M, Ramos JA: Comparison between brain dopaminergic neurons of juvenile and aged rats: sex-related differences. Mech Aging Dev 1992;63:45-55.
4. McDermott JL, Liu B, Dluzen DE: Sex differences and effects of estrogen on dopamine and DOPAC release from the striatum of male and female CD-1 mice. Exp Neurol 1994;125:306-311.
5. Becker JB: Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol.Biochem Behav 1999;64:803-812.
6. Dluzen DE, Mickley KR: Gender differences in modulatory effects of tamoxifen upon the nigrostriatal dopaminergic system. Pharmacol Biochem Behav 2005;80:27-33.
7. Brooks WJ, Jarvis MF, Wagner GC: Influence of sex, age and strain of MPTP-induced neurotoxicity. Res Commun Subst Abuse 1989;10:181-184.
8. Freyaldenhoven TE, Cadet JL, Ali SF: The dopamine-depleting effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent. Brain Res 1996;735:232-238.
9. Ali SF, Freyaldenhoven T: MPTP - A model of Parkinson's disease; in Bondy SC (ed): Chemicals and Neurodegenerative Disease. Scottsdale, Prominent Press, 1999, pp 161-180.
10. Gillies GE, Murray HE, Dexter D, McArthur S: Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson's disease. Pharmacol Biochem Behav 2004;78:513-522.
11. Murray HE, Pilai AV, McArthur SR, Razvi N, Dalta KP, Dexter DT, Gillies GE: Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 2003;116:213-222.
12. Wagner GC, Tekirian TL, Cheo CT: Sexual differences in sensitivity to methamphetamine toxicity. J Neural Transm Gen Sect 1993;93: 67-70.
13. Yu Y-L, Wagner GC: Influence of gonadal hormones on sexual differences in sensitivity to methamphetamine-induced neurotoxicity. J Neural Transm Park Dis Dement Sect 1994;8:215-221.
14. Miller DB, Ali SF, O'Callaghan JP, Laws SC: The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann NY Acad Sci 1998;844:153-156.
15. Yu L, Liao P-C: Estrogen and progesterone distinctly modulate methamphetamine-induced dopamine and serotonin depletins in C57BL/ 6J mice. J Neural Transm 2000;107:1139-1147.
16. Heller A, Bubula N, Lew R, Heller B, Won L: Gender-dependent enhanced adult neurotoxic response to methamphetamine following fetal exposure to the drug. J Pharmacol Exp Ther 2001;298:769-779.
17. Dluzen DE, McDermott JL, Anderson LI: Tamoxifen diminishes methamphetamine-induced striatal dopamine depletion in intact female and male mice. J Neuroendocrinol 2001;13:618-624.
18. Dluzen DE, Tweed C, Anderson LI, Laping NJ: Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the nigrostriatal dopaminergic system. Neuroendocrinology 2003;77:232-238.
19. Dluzen DE: The effect of gender and the neurotrophin, BDNF, upon methamphetamine-induced neurotoxicity of the nigrostriatal dopaminergic system in mice. Neurosci Lett 2004;359:135-138.
20. Brecht M-L, O'Brien A, von Mayrhauser C, Anglin MD: Methamphetamine use behaviors and gender differences. Addict Behav 2004;29:89-106.
21. Dluzen DE, Disshon KA, McDermott JL: Estrogen as a modulator of striatal dopaminergic neurotoxicity: in Marwah J, Tietelbaum H (eds): Recent Advances in Neurodegenerative Disorders. Socttsdale, Prominent Press, 1998, pp 149-192.
22. Baldereschi M, Di Carlo A, Rocca WA, Vanni P, Maggi S, Perissinotto E, Grigoletto F, Amaducci L, Inzitari D: Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000;55:1358-1363.
23. Bower JH, Maraganore DM, McDonnell SK, Rocca WA: Influence of strict, intermediate and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord 2000;15:819-825.
24. Schrag A, Jahanshahi M, Quinn NP: What contributes to depression in Parkinson's disease? Psychol Med 2001;31:65-73.
25. Swerdlow RH, Parks JK, Cassarino DS, Binder DR, Bennet JP Jr, Di Iori G, Golbe LI, Parker WD Jr: Biochemical analysis of hybrids expressing mitochondrial DNA from Contursi kindred Parkinson's subjects. Exp Neurol 2001;169:479-485.
26. Dluzen DE, Anderson LI, Pilati CF: Methamphetamine-gonadal steroid interactions: effects upon acute toxicity and striatal dopamine concentrations. Neurotoxicol Teratol 2002;24:267-273.
27. Hall JN, Broderick PM: Community networks for response to abuse outbreaks of methamphetamine and its analogs. NIDA Res Monogr 1991;115:109-120.
28. Yu L, Liao P-C: Sexual differences and estrous cycle in methamphetamine-induced dopamine and serotonin depletions in the striatum of mice. J Neural Transm 2000;107:419-427.
29. Dluzen DE, Horstink MWIM: Estrogen as a neuroprotectant of the nigrostriatal dopaminergic system. Endocrine 2003;21:67-75.
30. Cubells JF, Rayport S, Rajendran G, Sulzer D: Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J Neurosci 1994;14:2260-2271.
31. Seiden LS, Vosmer G: Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmacol Biochem Behav 1984;21:29-31.
32. Sulzer D, Chen TK, Lau YY, Kristensen H, Rayport S, Ewing A: Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 1995;15:4102-4108.
33. Sulzer D, Maidment NT, Rayport S: Amphetamine and other weak bases act to promote reverse transport of dopamine in ventral midbrain neurons. J Neurochem 1993;60:527-535.
34. Pifl C, Sitte HH, Reither H, Singer EA: The mechanism of the releasing action of amphetamine. Uptake, superfusion, and electrophysiological studies on transporter-transfected cells. Pure Appl Chem 2000;72:1045-1050.
35. Cadet JL, Jayanthi S, Deng X: Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 2003;17:1775-1788.
36. Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE: Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci 2001;21:1413-1419.
37. Bhatt SD, Dluzen DE: Dopamine transporter function differences between male and female CD-1 mice. Brain Res 2005;1035:188-195.
38. Myers RE, Anderson LI, Dluzen DE: Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice. Neuropharmacology 2003;44:624-632.
39. Gao X, Dluzen DE: Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 2001;103:385-394.
40. Gajjar TM, Anderson LI, Dluzen DE: Acute effects of estrogen upon methamphetamine induced neurotoxicity of the nigrostriatal dopaminergic system. J Neural Transm 2003;110:1215-1224.
41. D'Astous M, Gajjar TM, Dluzen DE, Di Paolo T: Dopamine transporter as a marker in methamphetamine-lesioned mice treated acutely with estradiol. Neuroendocrinology 2004;79:296-304.
42. Mickley KR, Dluzen DE: Dose-response effects of estrogen and tamoxifen upon methamphetamine-induced behavioral responses and neurotoxicity of the nigrostriatal dopaminergic system in female mice. Neuroendocrinology 2004;79:305-316.
43. Gao X, Dluzen DE: The effect of testosterone upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Brain Res 2001;892:63-69.
44. Lewis CM, Dluzen DE: Effect of testosterone upon methamphetamine-induced neurotoxicity of striatal dopamine within male and female mice. Soc Neurosci 2005;34:345.4.
45. Becker J, Ramirez VD: Dynamics of endogenous catecholamine release from brain fragments of male and female rats. Neuroendocrinology 1980;31:18-25.
46. Dluzen DE, McDermott JL, Liu B: Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996;18:603-606.
47. O'Dell SJ, Weihmuller FB, Marshall J: Multiple methamphetamine injections induce marked increases in extracellular striatal dopamine which correlate with subsequent neurotoxicity. Brain Res 1991;564:256-260.
48. Filloux F, Townsend JJ: Pre- and post-synaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 1993;119:79-88.
49. La Voie MJ, Hastings TG: Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 1999;19:1484-1491.
50. Burrows KB, Nixdorf WL, Yamamoto BK: Central administration of mehamphetamine synergizes with metabolic inhibition to deplete striatal monoamines. J Pharmacol Exp Ther 2000;292:853-860.